1. Generics Bulletin
  2. >>Business
  3. >>Deals

Teva Responds To API Unit Selloff Rumors

Company Says TAPI Remains ‘A Strong Business’ But Acknowledges Reports Of Sale

 
• By Dave Wallace

Amid rumors that Teva is mulling a potential sale of its APIs business, TAPI, the Israeli firm has underlined the strength of the unit while acknowledging that it continuously reviews such opportunities.

Deal - Yes or No? Spelled out on cubes
Rumors are swirling that Teva is mulling a deal for TAPI • Source: Shutterstock

Amid rumors of a potential sale by Teva of its Teva Active Pharmaceutical Ingredients unit, the generics giant has underlined the strength of the TAPI business and its increasingly standalone nature while acknowledging that it continuously reviews business opportunities.

A recent report in Bloomberg claimed that the generics giant was “weighing options for its active ingredients business, including a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Outgoing Cipla CEO On Key Wins, Unfinished Agenda, Biosimilars ‘Explosion’ To Come

 
• By Anju Ghangurde

Cipla’s global CEO and MD Umang Vohra is moving on handing over the baton to global COO, Achin Gupta. Vohra talks about his innings, where he sees Cipla in 2030 and the impact of the latest FDA action that aims to make biosimilar development faster and less costly.

‘Like A Kid In A Candy Store’ – Sandoz Sets Out Its Next Steps In Biosimilars

 
• By Dave Wallace

Expounding on the scale of the potential opportunity for biosimilars developers as the firm delivered its third-quarter results, Sandoz also set out launch plans for denosumab and aflibercept in Europe, as well as natalizumab in the US, by year-end.

Strides Partners With Incepta For Africa’s First Generic Contraceptive Injection

 
• By Urtė Fultinavičiūtė

Strides and Incepta’s partnership on the first generic injectable contraceptive marks a leap forward for many women in Africa to take control of their reproductive rights.

Celltrion Settlement Provides US Date For Aflibercept Entry

 
• By Dave Wallace

Just days after receiving FDA approval for its Eydenzelt biosimilar rival to Eylea, Celltrion has secured a US aflibercept launch date through a settlement with originator Regeneron. Meanwhile, new launches have helped to boost the Korean firm’s financials in Q3.

More from Business

‘A True Biosimilar’: Amgen Links Amjevita’s Success To Quality And Regulatory Stability

 
• By Dean Rudge

Amgen’s CEO Robert Bradway has reaffirmed confidence in the company’s Humira biosimilar, Amjevita, as the company tackles with an ever-growing population of denosumab biosimilars.

‘Right Thing To Do’: Teva Feels Validated By Partner-Driven Biosimilar Approach

 
• By Dean Rudge

The FDA’s proposal to streamline clinical trials is seen as vindication for Teva’s partnership-driven biosimilar play, as the firm targets $400m in added sales by 2027.

Outgoing Cipla CEO On Key Wins, Unfinished Agenda, Biosimilars ‘Explosion’ To Come

 
• By Anju Ghangurde

Cipla’s global CEO and MD Umang Vohra is moving on handing over the baton to global COO, Achin Gupta. Vohra talks about his innings, where he sees Cipla in 2030 and the impact of the latest FDA action that aims to make biosimilar development faster and less costly.